Oman Pharmaceutical Products (OPP) has entered its first
outsourcing partnership in Europe with Finnish company
Dragenopharm, providing the first step in its strategy to offer
contract manufacturing services globally.
Cardinal Health, the world's largest supplier of services to the
healthcare industry, is building its first tablet coating facility
to offer its pharmaceutical clients a range of innovative delivery
systems that target the oral...
Patheon has resumed normal production of Omnicef antibiotic powder
after it voluntarily suspended production in September at it
facility in Carolina, Puerto Rico, due to a US Food and Drug
Administration (FDA) manufacturing warning.
According to a new report, the demand for worldwide drug packaging
is expected to reach new heights, predicting growth of 5.3 per cent
annually to $24.3 billion (€20 7 billion) in 2009, driven by aging
demographic patterns increasing...
After a two-year tug-of-war, the World Trade Organization (WTO) has
solidified a landmark agreement to allow poor nations to import
generic versions of patented drugs to treat serious diseases or
A new report suggests that up to 30 biopharmaceutical products
developed by UK companies using cell-based manufacturing techniques
could be approved by 2012, reinforcing the idea that
biopharmaceuticals are increasingly being seen...
Merck is to cut 7,000 jobs, close five factories and three research
facilities, as the US pharmaceutical company continues to suffer
from the devastating repercussions caused by its painkiller Vioxx
and the pending lawsuits.
Avecia spin-off, Reaxa, has announced that Umicore has taken a 21
per cent stake in a move that underlines Reaxa's business strategy
in looking at joint R&D, new product development and toll
Chemical company Lanxess, release its third quarter results that
show restructuring strategy is bearing fruit, with sales up and the
reduction of net financial debt that is supported by strong growth
in the chemical industry.
Specialty chemical company Avecia featured prominently at the
recent CPhI Expo in Madrid, announcing investments and activity,
which hint at the business of custom synthesis of APIs and advanced
intermediates coming back into favour.
Sterling Biotech, India's largest gelatin producer, has struck a
deal with Gujarat Biotech (TGBL) to purchase its manufacturing unit
for Rs 55 cr ($12.3 million) in an all cash deal. Sterling's
acquisition brings it one...